Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Are there pediatric pharmacokinetic studies for Abasaglar® (insulin glargine)?

Eli Lilly and Company has no pharmacokinetic data of Abasaglar in pediatric patients. An independent study evaluated pharmacokinetics of insulin glargine in children.


Results from PK study with Insulin Glargine

Plasma trough concentrations of insulin glargine and its main 21A-Gly-human insulin (M1) and 21A-Gly-des-30B-Thr-human insulin (M2) metabolites

  • were similar to those observed in adult patients, and
  • provided no evidence for accumulation with chronic dosing.1,2

Patient details:

The PK study evaluated

  • 62 children
  • aged 2 to 6 years, and
  • with type 1 diabetes mellitus.1,2


1Danne T, Becker RHA, Ping L, Philotheou A. Insulin glargine metabolite 21A-Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study. Pediatr Diabetes. 2015;16(4):299-304. https://doi.org/10.1111/pedi.12161

2Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35(12):2626-2630. https://doi.org/10.2337/dc12-0270

Date of Last Review: April 13, 2021

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request